185 related articles for article (PubMed ID: 33020160)
1. Olorofim Susceptibility Testing of 1,423 Danish Mold Isolates Obtained in 2018-2019 Confirms Uniform and Broad-Spectrum Activity.
Astvad KMT; Jørgensen KM; Hare RK; Datcu R; Arendrup MC
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33020160
[TBL] [Abstract][Full Text] [Related]
2. EUCAST Determination of Olorofim (F901318) Susceptibility of Mold Species, Method Validation, and MICs.
Jørgensen KM; Astvad KMT; Hare RK; Arendrup MC
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784842
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.
Buil JB; Rijs AJMM; Meis JF; Birch M; Law D; Melchers WJG; Verweij PE
J Antimicrob Chemother; 2017 Sep; 72(9):2548-2552. PubMed ID: 28605488
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species.
Singh A; Singh P; Meis JF; Chowdhary A
J Antimicrob Chemother; 2021 Apr; 76(5):1229-1233. PubMed ID: 33421073
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus.
Kirchhoff L; Dittmer S; Buer J; Rath PM; Steinmann J
Int J Antimicrob Agents; 2020 Sep; 56(3):106105. PubMed ID: 32721601
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of olorofim against Aspergillus fumigatus sensu lato clinical isolates: activity is retained against isolates showing resistance to azoles and/or amphotericin B.
Escribano P; Gómez A; Reigadas E; Muñoz P; Guinea J;
Clin Microbiol Infect; 2022 Sep; 28(9):1291.e7-1291.e10. PubMed ID: 35597509
[TBL] [Abstract][Full Text] [Related]
7.
Talbot JJ; Frisvad JC; Meis JF; Hagen F; Verweij PE; Hibbs DE; Lai F; Groundwater PW; Samson RA; Kidd SE; Barrs VR; Houbraken J
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451501
[TBL] [Abstract][Full Text] [Related]
8. Resistance profiling of
Buil JB; Oliver JD; Law D; Baltussen T; Zoll J; Hokken MWJ; Tehupeiory-Kooreman M; Melchers WJG; Birch M; Verweij PE
Emerg Microbes Infect; 2022 Dec; 11(1):703-714. PubMed ID: 35109772
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies.
Rivero-Menendez O; Cuenca-Estrella M; Alastruey-Izquierdo A
J Antimicrob Chemother; 2019 Jun; 74(6):1586-1590. PubMed ID: 30891600
[TBL] [Abstract][Full Text] [Related]
10. EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates.
Jørgensen KM; Astvad KMT; Hare RK; Arendrup MC
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910898
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Activity of Novel Antifungal Olorofim against Filamentous Fungi and Comparison to Eight Other Antifungal Agents.
Georgacopoulos O; Nunnally NS; Ransom EM; Law D; Birch M; Lockhart SR; Berkow EL
J Fungi (Basel); 2021 May; 7(5):. PubMed ID: 34065811
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Activity of ASP2397 against Aspergillus Isolates with or without Acquired Azole Resistance Mechanisms.
Arendrup MC; Jensen RH; Cuenca-Estrella M
Antimicrob Agents Chemother; 2016 Jan; 60(1):532-6. PubMed ID: 26552973
[TBL] [Abstract][Full Text] [Related]
13. Revision of EUCAST breakpoints: consequences for susceptibility of contemporary Danish mould isolates to isavuconazole and comparators.
Jørgensen KM; Guinea J; Meletiadis J; Hare RK; Arendrup MC
J Antimicrob Chemother; 2020 Sep; 75(9):2573-2581. PubMed ID: 32556315
[TBL] [Abstract][Full Text] [Related]
14. EUCAST-Obtained Olorofim MICs against Aspergillus and Scedosporium Species and Lomentospora prolificans Showed High Agreements between Visual Inspection and Spectrophotometric Readings.
Escribano P; Gómez A; Reigadas E; Muñoz P; Guinea J;
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0084922. PubMed ID: 35924916
[TBL] [Abstract][Full Text] [Related]
15. Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei.
Lackner M; Birch M; Naschberger V; Grässle D; Beckmann N; Warn P; Gould J; Law D; Lass-Flörl C; Binder U
J Antimicrob Chemother; 2018 Nov; 73(11):3068-3073. PubMed ID: 30351438
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Olorofim (F901318) against
Seyedmousavi S; Chang YC; Law D; Birch M; Rex JH; Kwon-Chung KJ
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30885903
[TBL] [Abstract][Full Text] [Related]
17.
Jørgensen KM; Astvad KMT; Arendrup MC
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513793
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates.
Astvad KMT; Hare RK; Arendrup MC
Clin Microbiol Infect; 2017 Nov; 23(11):882-887. PubMed ID: 28373148
[TBL] [Abstract][Full Text] [Related]
19. Olorofim Effectively Eradicates Dermatophytes
Mirbzadeh Ardakani E; Sharifirad A; Pashootan N; Nayebhashemi M; Zahmatkesh M; Enayati S; Razzaghi-Abyaneh M; Khalaj V
Antimicrob Agents Chemother; 2021 Nov; 65(12):e0138621. PubMed ID: 34570652
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies.
Rivero-Menendez O; Cuenca-Estrella M; Alastruey-Izquierdo A
J Antimicrob Chemother; 2020 Dec; 75(12):3582-3585. PubMed ID: 32856079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
